Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) FCF Margin (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed FCF Margin for 9 consecutive years, with 870.74% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin changed N/A year-over-year to 870.74%; the TTM value through Mar 2026 reached 151850.0%, changed N/A, while the annual FY2025 figure was 659.45%, N/A changed from the prior year.
  • FCF Margin hit 870.74% in Q1 2026 for Crescent Biopharma, down from 1546.04% in the prior quarter.
  • Across five years, FCF Margin topped out at 1546.04% in Q2 2025 and bottomed at 21695.8% in Q2 2022.
  • Average FCF Margin over 3 years is 7006.83%, with a median of 870.74% recorded in 2026.
  • On a YoY basis, FCF Margin climbed as much as 956740984bps in 2022 and fell as far as 956740984bps in 2022.
  • Crescent Biopharma's FCF Margin stood at 21695.8% in 2022, then soared by 107bps to 1546.04% in 2025, then plummeted by -156bps to 870.74% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 870.74%, 1546.04%, and 21695.8% for Q1 2026, Q2 2025, and Q2 2022 respectively.